Thyroid cancer is the most common endocrine cancer. The discovery of new biomarkers for
thyroid cancer has significantly improved the understanding of the molecular pathogenesis …

Trophoblast research over the past decades has underlined the striking similarities between
the proliferative, migratory and invasive properties of placental cells and those of cancer …

Purpose Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial
growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial …

Background The expression of vascular endothelial growth factor (VEGF) is characteristic of
differentiated thyroid cancer and is associated with aggressive tumor behavior and a poor …

Objectives: Until recently, treatment options for patients with progressive, radioactive iodine-
resistant differentiated thyroid cancer (DTC) have been limited. In our clinical practice, we …

Background: Vascular endothelial growth factor (VEGF-A) expression is upregulated in the
majority of human tumors, where it stimulates proliferation, migration, and survival of …

Therapeutic options for patients with metastatic medullary thyroid carcinoma (MTC) are
limited due to lack of effective treatments. Thus, there is a need to thoroughly characterize …

Background Multicellular tumor spheroids (MCTS) formed scaffold-free under microgravity
are of high interest for research and medicine. Their formation mechanism can be studied in …

The incidence of human papillary thyroid cancer (PTC) is increasing and an aggressive
subtype of this disease is resistant to treatment with vascular endothelial growth factor …

Context: Antiangiogenic therapies have shown potential in the treatment of advanced thyroid
cancer, but it is uncertain which patients are most likely to benefit from therapy. Objective …